Pharmaceutical giant Pfizer has partnered with digital health company Anumana, a company founded in 2021 in collaboration with the Mayo Clinic Platform, to develop an artificial intelligence electrocardiogram algorithm used for the detection of cardiac amyloidosis.
Through the partnership, Anumana will conduct a clinical trial and seek regulatory approval, according to a Dec. 15 Anumana news release.
"The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress," Anumana Chief Business Officer David McMullin said. "We believe this collaboration will demonstrate the power of Anumana's AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives."